News Chart Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Real-time Estimate Cboe BZX Other stock markets 01:24:55 2024-06-05 pm EDT			5-day change	1st Jan Change
135.6 ^USD	+1.60%		+0.86%	+3.05%

Jun. 03	Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	CI
Jun. 03	Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	CI

3d73023d2c6f68ff701ad1b.1gA8TlZwOecsSdo1s2lbWtwl14yzZjQ2QP28aGHr2e4.jG9ENwU0cqNnEKhZ3yA9DJl0n-j1EH5uN5PUXTear7aXeQQRCRkLhnlx7g~d4051470194da2eda394325781179ec4